JP7637616B2 - 厳密な活性剤溶解プロファイルを有する口腔用フィルム組成物及び剤形 - Google Patents

厳密な活性剤溶解プロファイルを有する口腔用フィルム組成物及び剤形 Download PDF

Info

Publication number
JP7637616B2
JP7637616B2 JP2021512652A JP2021512652A JP7637616B2 JP 7637616 B2 JP7637616 B2 JP 7637616B2 JP 2021512652 A JP2021512652 A JP 2021512652A JP 2021512652 A JP2021512652 A JP 2021512652A JP 7637616 B2 JP7637616 B2 JP 7637616B2
Authority
JP
Japan
Prior art keywords
film
commercially available
hydrochloride
active agent
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021512652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021536466A (ja
JP2021536466A5 (cg-RX-API-DMAC10.html
Inventor
アレクサンダー マーク ショベル
ステファン ワルガッキ
ヴィンセント ジェイ ボーノ
スーザン シュマード
クリストファー ジェームス サンティー
Original Assignee
アクエスティブ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクエスティブ セラピューティクス インコーポレイテッド filed Critical アクエスティブ セラピューティクス インコーポレイテッド
Publication of JP2021536466A publication Critical patent/JP2021536466A/ja
Publication of JP2021536466A5 publication Critical patent/JP2021536466A5/ja
Priority to JP2025023573A priority Critical patent/JP2025093925A/ja
Application granted granted Critical
Publication of JP7637616B2 publication Critical patent/JP7637616B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021512652A 2018-09-07 2019-09-05 厳密な活性剤溶解プロファイルを有する口腔用フィルム組成物及び剤形 Active JP7637616B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025023573A JP2025093925A (ja) 2018-09-07 2025-02-17 厳密な活性剤溶解プロファイルを有する口腔用フィルム組成物及び剤形

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862728187P 2018-09-07 2018-09-07
US62/728,187 2018-09-07
US201862732720P 2018-09-18 2018-09-18
US62/732,720 2018-09-18
PCT/US2019/049725 WO2020051317A1 (en) 2018-09-07 2019-09-05 Oral film compositions and dosage forms having precise active dissolution profiles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025023573A Division JP2025093925A (ja) 2018-09-07 2025-02-17 厳密な活性剤溶解プロファイルを有する口腔用フィルム組成物及び剤形

Publications (3)

Publication Number Publication Date
JP2021536466A JP2021536466A (ja) 2021-12-27
JP2021536466A5 JP2021536466A5 (cg-RX-API-DMAC10.html) 2022-09-13
JP7637616B2 true JP7637616B2 (ja) 2025-02-28

Family

ID=68425244

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021512652A Active JP7637616B2 (ja) 2018-09-07 2019-09-05 厳密な活性剤溶解プロファイルを有する口腔用フィルム組成物及び剤形
JP2025023573A Pending JP2025093925A (ja) 2018-09-07 2025-02-17 厳密な活性剤溶解プロファイルを有する口腔用フィルム組成物及び剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025023573A Pending JP2025093925A (ja) 2018-09-07 2025-02-17 厳密な活性剤溶解プロファイルを有する口腔用フィルム組成物及び剤形

Country Status (7)

Country Link
US (5) US11541002B2 (cg-RX-API-DMAC10.html)
EP (1) EP3846778A1 (cg-RX-API-DMAC10.html)
JP (2) JP7637616B2 (cg-RX-API-DMAC10.html)
CN (2) CN112955124A (cg-RX-API-DMAC10.html)
BR (1) BR112021004053A2 (cg-RX-API-DMAC10.html)
CA (1) CA3110997A1 (cg-RX-API-DMAC10.html)
WO (1) WO2020051317A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210346385A1 (en) * 2018-09-21 2021-11-11 MSB Holdings, Inc Taste-masked dosage forms
US11331309B2 (en) * 2019-06-05 2022-05-17 Cure Pharmaceutical Holding Corp. Methods and compositions for improving sleep
EP3895692A1 (en) * 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Oral thin film with smooth fused film
CN112697937A (zh) * 2020-12-18 2021-04-23 卓和药业集团有限公司 泊沙康唑肠溶片溶出度的分析方法
US20220347117A1 (en) * 2021-03-09 2022-11-03 Aquestive Therapeutics, Inc. Dosage forms having equivalent biocomparable profiles
CN113311124B (zh) * 2021-06-08 2023-11-14 湖南慧泽生物医药科技有限公司 模拟药剂在体释放及吸收过程的二室模型实验装置
CN115671078A (zh) * 2021-07-28 2023-02-03 上海博志研新药物技术有限公司 一种依匹斯汀口溶膜组合物、其制备方法及应用
CN114010575B (zh) * 2021-10-22 2024-06-28 江苏谛奇医药科技有限公司 新斯的明及其衍生物的新制剂
KR20240093850A (ko) * 2021-10-22 2024-06-24 어퀘스티브 테라퓨틱스, 아이엔씨. 개선된 안정성 프로파일을 갖는 약제학적 조성물
WO2023078366A1 (zh) * 2021-11-04 2023-05-11 上海博志研新药物技术有限公司 一种盐酸鲁拉西酮口溶膜组合物、其制备方法及应用
CN116211833A (zh) * 2021-11-30 2023-06-06 南京海辰药业股份有限公司 一种咪唑立宾口腔速溶膜剂及其制备方法
CN114983984B (zh) * 2022-07-26 2023-09-01 山东达因海洋生物制药股份有限公司 一种用于哮喘治疗复方口溶膜剂及其制备方法
CN119909044A (zh) * 2023-10-31 2025-05-02 浙江紫藤药业科技有限公司 一种口腔膜剂及其制备方法
JP7659339B1 (ja) 2023-11-21 2025-04-09 東海カプセル株式会社 ピモベンダンを含有する経口フィルム製剤
CN117414352A (zh) * 2023-11-22 2024-01-19 湖北广济医药科技有限公司 一种瑞美吉泮口溶膜剂及其制备方法
CN117631135B (zh) * 2024-01-25 2024-04-09 四川大学 一种双功能柔性水凝胶光纤及其制备方法和应用
CN118576571B (zh) * 2024-05-31 2025-02-14 浙江大学 一种药物释放曲线可定制的口服膜剂及其制备方法
WO2025261492A1 (zh) * 2024-06-20 2025-12-26 广州玻思韬控释药业有限公司 一种秋水仙碱膜剂
TW202604479A (zh) * 2024-06-26 2026-02-01 大陸商浙江同源康醫藥股份有限公司 依達拉奉口腔溶膜速釋製劑組合物及其製劑和用途
US20260027045A1 (en) * 2024-07-23 2026-01-29 Aquestive Therapeutics, Inc. Methods of administering enhanced delivery epinephrine and prodrug compositions
CN119139272A (zh) * 2024-09-02 2024-12-17 华中药业股份有限公司 一种艾司唑仑口腔速溶膜剂及其制备方法
CN118903065B (zh) * 2024-10-12 2025-02-07 山东则正医药技术有限公司 一种卢美哌隆口溶膜掩味组合物、其制备方法及应用
WO2026150511A1 (ja) * 2025-01-08 2026-07-16 東海カプセル株式会社 ピモベンダンを含有する経口フィルム製剤
CN119970685B (zh) * 2025-02-18 2025-10-14 杭州成邦医药科技有限公司 一种卢美哌隆或其盐的膜剂与其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013253039A (ja) 2012-06-07 2013-12-19 Kyukyu Yakuhin Kogyo Kk 口腔内溶解型フィルム製剤
WO2017192923A1 (en) 2016-05-05 2017-11-09 Monosol Rx, Llc Pharmaceutical compositions with enhanced permeation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631837A (en) 1985-05-31 1986-12-30 Magoon Richard E Method and apparatus for drying fruit pulp and the like
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
WO2000077001A1 (en) 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
CA2516291C (en) 2003-02-28 2012-02-14 Alk-Abello A/S Dosage form having a saccharide matrix
US8012505B2 (en) * 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US7906140B2 (en) * 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
ES2530090T3 (es) 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
CA2725342C (en) 2008-05-27 2024-02-20 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders
EP2448554A4 (en) 2009-06-29 2014-03-12 Oreal REFRESHING CREAM BASE IN YELLOW
WO2011053251A1 (en) 2009-10-30 2011-05-05 Ix Biopharma Pte Ltd Fast dissolving solid dosage form
US8956685B2 (en) 2010-02-24 2015-02-17 Monosol Rx, Llc Use of dams to improve yield in film processing
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
CN108175762A (zh) 2010-09-23 2018-06-19 莫诺索尔克斯有限公司 用于直接在包装表面上形成药用产品的方法和系统
US11129799B2 (en) 2011-04-12 2021-09-28 Aquestive Therapeutics, Inc. Dual lane coating
US20130156823A1 (en) * 2011-12-20 2013-06-20 MAP Pharmacauticals, Inc. Excipient-free Aerosol Formulation
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
CA2953546A1 (en) * 2014-06-24 2015-12-30 Taho Pharmaceuticals Fast acting orally disintegrating film
KR20170117374A (ko) * 2014-12-09 2017-10-23 모노졸 알엑스, 엘엘씨 선형 다당류-기반 필름 생성물
CN105193772A (zh) * 2015-10-28 2015-12-30 陈跃坚 一种沙格列汀口腔膜剂及其制备方法
CN122182527A (zh) * 2016-05-05 2026-06-12 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013253039A (ja) 2012-06-07 2013-12-19 Kyukyu Yakuhin Kogyo Kk 口腔内溶解型フィルム製剤
WO2017192923A1 (en) 2016-05-05 2017-11-09 Monosol Rx, Llc Pharmaceutical compositions with enhanced permeation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A novel unit-doseapproach for the pharmaceutical compounding of an orodispersible film,International Jouranl of Pharmaceutics,2018年,539(1-2),165-174
Design Optimization and In Vitro-In Vivo Evaluation of Orally Dissolving Strips of Clobazam,J Drug Deliv,2014年,Volumne 2014,392783,1-15,https://doi.org/10.1155/2014/392783

Also Published As

Publication number Publication date
US11541002B2 (en) 2023-01-03
JP2021536466A (ja) 2021-12-27
JP2025093925A (ja) 2025-06-24
CN120789028A (zh) 2025-10-17
US20230149304A1 (en) 2023-05-18
US12290597B2 (en) 2025-05-06
US20230145752A1 (en) 2023-05-11
WO2020051317A1 (en) 2020-03-12
US20250339367A1 (en) 2025-11-06
US12403090B2 (en) 2025-09-02
US20260034059A1 (en) 2026-02-05
BR112021004053A2 (pt) 2021-05-25
CA3110997A1 (en) 2020-03-12
EP3846778A1 (en) 2021-07-14
CN112955124A (zh) 2021-06-11
US20200101009A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
US12290597B2 (en) Oral film compositions and dosage forms having precise active dissolution profiles
US12310922B2 (en) System and method for making personalized individual unit doses containing pharmaceutical actives
US20210128511A1 (en) Prodrug compositions and methods of treatment
US20210145731A1 (en) Multimodal compositions and methods of treatment
US20220233471A1 (en) Prodrug compositions and methods of treatment
US20220347117A1 (en) Dosage forms having equivalent biocomparable profiles
US12465564B2 (en) Oral and nasal compositions and methods of treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220905

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250217

R150 Certificate of patent or registration of utility model

Ref document number: 7637616

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150